Skip to main content

The head of Bombardier Inc. says the continuation of its regional jet program hinges on whether the company can fill up the CRJ’s partly blank order book.

“We’re trying to keep this product line going, because there’s only two competitors there,” Alain Bellemare said.

“But it depends if we can fill up the backlog.”

Story continues below advertisement

“We’re assessing options as we speak, so we’ll see where it goes,” he said Tuesday.

The plane-and-train-maker’s backlog of 54 CRJ 900 planes extends only through the end of next year, according to Bombardier.

Once a cash cow for the Montreal-based company, the CRJ now loses money, Bellemare has said. For the past five years Embraer SA’s E175 narrow-body aircraft has dominated the U.S. market, where the majority of regional jets are sold.

Quebec’s economy minister has said the government is prepared to work with Bombardier if it needs help with its regional jet program, though Premier Francois Legault has stated that likely won’t involve financial support for the jetliner.

Bombardier is placing renewed focus on its business jets, whose robust sales and high earnings margin in 2018 propelled the company to its first annual profit in five years.

In July, the company sold a majority share of its C Series commercial aircraft program to Europe’s Airbus SE, which rebranded it the Airbus A220.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies